ES2894903T3 - Profármacos antagonistas de NMDA - Google Patents
Profármacos antagonistas de NMDA Download PDFInfo
- Publication number
- ES2894903T3 ES2894903T3 ES19166031T ES19166031T ES2894903T3 ES 2894903 T3 ES2894903 T3 ES 2894903T3 ES 19166031 T ES19166031 T ES 19166031T ES 19166031 T ES19166031 T ES 19166031T ES 2894903 T3 ES2894903 T3 ES 2894903T3
- Authority
- ES
- Spain
- Prior art keywords
- pyridin
- phenyl
- ethanamine
- pyrrolidine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)(C)C1N(*)CCC1 Chemical compound CC(C)(C)C1N(*)CCC1 0.000 description 3
- KQQGZRYBXLFQEP-ZLBDCPSSSA-N CC(C)(C)OC(NCCCC[C@@H](C(N(CCC1)C1C(N[C@@H](Cc1ncccc1)c1ccccc1)=O)=O)NC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(NCCCC[C@@H](C(N(CCC1)C1C(N[C@@H](Cc1ncccc1)c1ccccc1)=O)=O)NC(OC(C)(C)C)=O)=O KQQGZRYBXLFQEP-ZLBDCPSSSA-N 0.000 description 1
- SQTNUUQFWZWAOX-UHFFFAOYSA-N CC(C)C(OC(C(C)C)=O)OC(Oc(cc1)ccc1S(C)(=O)=O)=O Chemical compound CC(C)C(OC(C(C)C)=O)OC(Oc(cc1)ccc1S(C)(=O)=O)=O SQTNUUQFWZWAOX-UHFFFAOYSA-N 0.000 description 1
- JHGDCIXPGKTMJU-PKHIMPSTSA-N CC(C)C(OC(C)OC(N[C@@H](Cc1ncccc1)c1ccccc1)=O)=O Chemical compound CC(C)C(OC(C)OC(N[C@@H](Cc1ncccc1)c1ccccc1)=O)=O JHGDCIXPGKTMJU-PKHIMPSTSA-N 0.000 description 1
- SVHRMWZPCNHENV-UHFFFAOYSA-N CC(C)C(OC(C)OC(Oc(cc1)ccc1S(C)(=O)=O)=O)=O Chemical compound CC(C)C(OC(C)OC(Oc(cc1)ccc1S(C)(=O)=O)=O)=O SVHRMWZPCNHENV-UHFFFAOYSA-N 0.000 description 1
- ILUWVORABZTBIU-UHFFFAOYSA-N CC(C)C(OCCl)=O Chemical compound CC(C)C(OCCl)=O ILUWVORABZTBIU-UHFFFAOYSA-N 0.000 description 1
- HDEPIBOBWYNTAW-ACRUOGEOSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1C(N[C@@H](Cc1ncccc1)c1ccccc1)=O)=O)N Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1C(N[C@@H](Cc1ncccc1)c1ccccc1)=O)=O)N HDEPIBOBWYNTAW-ACRUOGEOSA-N 0.000 description 1
- FTZDWXHJDXKQTP-JRZJBTRGSA-N CC(OC(C)=O)OC(N[C@@H](Cc1ncccc1)c1ccccc1)=O Chemical compound CC(OC(C)=O)OC(N[C@@H](Cc1ncccc1)c1ccccc1)=O FTZDWXHJDXKQTP-JRZJBTRGSA-N 0.000 description 1
- ILBPCAMGDUCMOB-UHFFFAOYSA-N CC(OC(C)=O)OC(Oc(cc1)ccc1S(C)(=O)=O)=O Chemical compound CC(OC(C)=O)OC(Oc(cc1)ccc1S(C)(=O)=O)=O ILBPCAMGDUCMOB-UHFFFAOYSA-N 0.000 description 1
- BEEHQODUONYQIO-FKBYEOEOSA-N NCCCC[C@@H](C(N(CCC1)[C@@H]1C(N[C@@H](Cc1ncccc1)c1ccccc1)=O)=O)N Chemical compound NCCCC[C@@H](C(N(CCC1)[C@@H]1C(N[C@@H](Cc1ncccc1)c1ccccc1)=O)=O)N BEEHQODUONYQIO-FKBYEOEOSA-N 0.000 description 1
- XLAQXQQLKCSLFC-FKBYEOEOSA-N N[C@@H](Cc1c[nH]cn1)C(N(CCC1)[C@@H]1C(N[C@@H](Cc1ncccc1)c1ccccc1)=O)=O Chemical compound N[C@@H](Cc1c[nH]cn1)C(N(CCC1)[C@@H]1C(N[C@@H](Cc1ncccc1)c1ccccc1)=O)=O XLAQXQQLKCSLFC-FKBYEOEOSA-N 0.000 description 1
- QGGHOUZHWORCTD-IRXDYDNUSA-N O=C([C@H]1NCCC1)N[C@@H](Cc1ncccc1)c1ccccc1 Chemical compound O=C([C@H]1NCCC1)N[C@@H](Cc1ncccc1)c1ccccc1 QGGHOUZHWORCTD-IRXDYDNUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361899903P | 2013-11-05 | 2013-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2894903T3 true ES2894903T3 (es) | 2022-02-16 |
Family
ID=51947383
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14802476T Active ES2733344T3 (es) | 2013-11-05 | 2014-10-30 | Profármacos antagonistas de NMDA |
| ES19166031T Active ES2894903T3 (es) | 2013-11-05 | 2014-10-30 | Profármacos antagonistas de NMDA |
| ES21196371T Active ES2999064T3 (en) | 2013-11-05 | 2014-10-30 | Nmda antagonist prodrugs |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14802476T Active ES2733344T3 (es) | 2013-11-05 | 2014-10-30 | Profármacos antagonistas de NMDA |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21196371T Active ES2999064T3 (en) | 2013-11-05 | 2014-10-30 | Nmda antagonist prodrugs |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9822075B2 (OSRAM) |
| EP (3) | EP3066091B1 (OSRAM) |
| JP (4) | JP6479834B2 (OSRAM) |
| KR (2) | KR102336426B1 (OSRAM) |
| CN (2) | CN105683180B (OSRAM) |
| AR (1) | AR098319A1 (OSRAM) |
| AU (1) | AU2014345407B2 (OSRAM) |
| CA (1) | CA2928004C (OSRAM) |
| CY (1) | CY1121749T1 (OSRAM) |
| DK (1) | DK3066091T3 (OSRAM) |
| ES (3) | ES2733344T3 (OSRAM) |
| HR (2) | HRP20241784T1 (OSRAM) |
| HU (2) | HUE045001T2 (OSRAM) |
| LT (1) | LT3066091T (OSRAM) |
| MX (2) | MX377276B (OSRAM) |
| PL (2) | PL3066091T3 (OSRAM) |
| PT (1) | PT3066091T (OSRAM) |
| RS (2) | RS58991B1 (OSRAM) |
| RU (1) | RU2695372C2 (OSRAM) |
| SI (1) | SI3066091T1 (OSRAM) |
| SM (1) | SMT202500023T1 (OSRAM) |
| TR (1) | TR201909632T4 (OSRAM) |
| TW (1) | TW201609653A (OSRAM) |
| UY (1) | UY35823A (OSRAM) |
| WO (1) | WO2015067923A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105683180B (zh) | 2013-11-05 | 2020-01-21 | 阿斯利康(瑞典)有限公司 | Nmda拮抗剂前药 |
| WO2018098344A1 (en) * | 2016-11-28 | 2018-05-31 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of lanicemine and their method of use |
| CN107578281B (zh) * | 2017-08-31 | 2021-03-30 | 湖南大学 | 电子商务环境下用户优惠券行为预测方法及模型构建方法 |
| KR20230026449A (ko) * | 2020-06-23 | 2023-02-24 | 바이오하벤 테라퓨틱스 리미티드 | (1s)-1-페닐-2-피리딘-2-일레탄아민의 국소 제형 |
| WO2025137661A1 (en) * | 2023-12-22 | 2025-06-26 | Biohaven Therapeutics Ltd. | Combination treatment of neurological disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7909514L (sv) * | 1979-11-16 | 1981-05-17 | Astra Laekemedel Ab | Nya halofenyl-pyridyl-allylaminderivat |
| US4769466A (en) * | 1987-02-06 | 1988-09-06 | Pennwalt Corporation | 2-aminoacetamide pyridinyl derivatives |
| SG52662A1 (en) * | 1988-08-12 | 1998-09-28 | Astra Ab | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties |
| UA29437C2 (uk) | 1992-04-03 | 2000-11-15 | Астра АБ | (s)-альфа-феніл-2-піридинетанамін або його сіль з неорганічною кислотою, які мають протисудомну активність, спосіб їх отримання, лікарський препарат на їх основі та спосіб лікування судом |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| US6613879B1 (en) * | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
| US6407235B1 (en) | 2000-08-21 | 2002-06-18 | Hoffmann-La Roche Inc. | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol |
| JP4216713B2 (ja) * | 2001-06-11 | 2009-01-28 | ゼノポート，インコーポレイティド | Ｇａｂａ類似体のプロドラッグ、組成物およびその使用 |
| GB0310593D0 (en) | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
| JP4927563B2 (ja) | 2003-12-30 | 2012-05-09 | ゼノポート，インコーポレイティド | アシルオキシアルキルカルバメートプロドラッグ及び中間体の合成 |
| CA2621847A1 (en) * | 2005-09-08 | 2007-03-15 | Shire Llc | Prodrugs of t3 and t4 with enhanced bioavailability |
| CN101246417B (zh) | 2007-02-13 | 2010-09-29 | 艾威梯科技(北京)有限公司 | 音频数据流输入/输出无间断软件切换的方法和系统 |
| ES2601852T3 (es) | 2008-01-25 | 2017-02-16 | Xenoport, Inc. | Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso |
| US8299291B2 (en) | 2008-08-07 | 2012-10-30 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
| WO2011089216A1 (en) * | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| WO2013023155A1 (en) * | 2011-08-11 | 2013-02-14 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use |
| CN105683180B (zh) | 2013-11-05 | 2020-01-21 | 阿斯利康(瑞典)有限公司 | Nmda拮抗剂前药 |
-
2014
- 2014-10-30 CN CN201480060416.0A patent/CN105683180B/zh active Active
- 2014-10-30 EP EP14802476.3A patent/EP3066091B1/en active Active
- 2014-10-30 HU HUE14802476A patent/HUE045001T2/hu unknown
- 2014-10-30 TR TR2019/09632T patent/TR201909632T4/tr unknown
- 2014-10-30 ES ES14802476T patent/ES2733344T3/es active Active
- 2014-10-30 RS RS20190821A patent/RS58991B1/sr unknown
- 2014-10-30 WO PCT/GB2014/053236 patent/WO2015067923A1/en not_active Ceased
- 2014-10-30 AU AU2014345407A patent/AU2014345407B2/en active Active
- 2014-10-30 MX MX2016005567A patent/MX377276B/es active IP Right Grant
- 2014-10-30 SI SI201431242T patent/SI3066091T1/sl unknown
- 2014-10-30 US US15/034,727 patent/US9822075B2/en active Active
- 2014-10-30 LT LTEP14802476.3T patent/LT3066091T/lt unknown
- 2014-10-30 DK DK14802476.3T patent/DK3066091T3/da active
- 2014-10-30 MX MX2020011946A patent/MX394633B/es unknown
- 2014-10-30 EP EP19166031.5A patent/EP3564234B1/en active Active
- 2014-10-30 ES ES19166031T patent/ES2894903T3/es active Active
- 2014-10-30 HU HUE21196371A patent/HUE070532T2/hu unknown
- 2014-10-30 PL PL14802476T patent/PL3066091T3/pl unknown
- 2014-10-30 KR KR1020167014625A patent/KR102336426B1/ko active Active
- 2014-10-30 RS RS20241459A patent/RS66369B1/sr unknown
- 2014-10-30 PT PT14802476T patent/PT3066091T/pt unknown
- 2014-10-30 RU RU2016119493A patent/RU2695372C2/ru active
- 2014-10-30 ES ES21196371T patent/ES2999064T3/es active Active
- 2014-10-30 PL PL21196371.5T patent/PL4001272T3/pl unknown
- 2014-10-30 HR HRP20241784TT patent/HRP20241784T1/hr unknown
- 2014-10-30 JP JP2016551069A patent/JP6479834B2/ja active Active
- 2014-10-30 CA CA2928004A patent/CA2928004C/en active Active
- 2014-10-30 SM SM20250023T patent/SMT202500023T1/it unknown
- 2014-10-30 EP EP21196371.5A patent/EP4001272B1/en active Active
- 2014-10-30 HR HRP20191159TT patent/HRP20191159T1/hr unknown
- 2014-10-30 CN CN202010014023.3A patent/CN111187202B/zh active Active
- 2014-10-30 KR KR1020217039470A patent/KR102469167B1/ko active Active
- 2014-11-05 AR ARP140104166A patent/AR098319A1/es unknown
- 2014-11-05 UY UY0001035823A patent/UY35823A/es not_active Application Discontinuation
- 2014-11-05 TW TW103138423A patent/TW201609653A/zh unknown
-
2017
- 2017-10-17 US US15/785,654 patent/US10207994B2/en active Active
-
2019
- 2019-01-20 US US16/252,648 patent/US10815199B2/en active Active
- 2019-02-05 JP JP2019018440A patent/JP6633233B2/ja active Active
- 2019-07-02 CY CY20191100691T patent/CY1121749T1/el unknown
- 2019-12-10 JP JP2019222567A patent/JP6856737B2/ja active Active
-
2020
- 2020-10-26 US US17/079,553 patent/US20210040039A1/en active Pending
-
2021
- 2021-03-18 JP JP2021044193A patent/JP7234278B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7234278B2 (ja) | Ｎｍｄａアンタゴニストプロドラッグ | |
| TW200843778A (en) | Pterin analogs | |
| HK40076024B (en) | Nmda antagonist prodrugs | |
| HK40076024A (en) | Nmda antagonist prodrugs | |
| HK40014361A (en) | Nmda antagonist prodrugs | |
| HK40014361B (en) | Nmda antagonist prodrugs | |
| US20210253642A1 (en) | Calpain modulators and therapeutic uses thereof background | |
| HK1226721A1 (en) | Nmda antagonist prodrugs | |
| HK1226721B (en) | Nmda antagonist prodrugs | |
| BR112016009949B1 (pt) | Composto pró-fármaco antagonista de nmda, composição farmacêutica, e, uso de um composto |